The article you linked was very good in speaking about the Brilacidin trial and the attractiveness about it for investors. But what caught my attention most was the last paragraph copied below
-------------------------------------------------------------
"Microcapdaily has been covering IPIX for years starting with CTIX back in 2015 reporting on the stocks legendary run to $4.93 per share. We stated on CTIX back in the day: “As anyone in the industry knows, regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with no success thus far. It seems Kevetrin(TM) has accomplished this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers. The market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually, he adds.”
Investor sentiment in IPIX is high
-------------------------------------------------------------------------
This paragraph above should make any investor (not trader, they don't give a damn except for dollars put in their pockets today, tomorrow, or next week) realize the opportunity IPIX currently provides them; not just one platform drug that could change medicine but two that could both be revenue generators in the $10+B range per year. Kevetrin should be a revolutionary cancer drug on its own but it has as much OR MORE potential as a complementary aid to ALL current cancer treatments due to its safety and ability to soften the toxicity of these other treatments. On a financial basis, it would also allow all the BPs that are coming to the end of the patent life for their cancer drugs to market the new Kevetrin-added "cocktail" as a new drug with a brand new term of patent coverage, thus all BPs will be testing it once we get it approved in pill form (pill formulation is completed and was about 1/2 way through toxological tests before IPIX ran out of money and is waiting to complete them once IPIX secures the funds necessary to do so). The final tox tests should not take that long once they get re-started.
The above paragraph obviously brings up the point - If solving the puzzle of activating the p53 gene, the "Guardian Angel" gene, the most highly researched topic in the HISTORY of medicine, why has Kevetrin been sitting on the shelf languishing for less than a drop in the bucket of dollars put into cancer research a year?
The only logical conclusion is that government, big pharma, cancer research funds, and others don't want to cure cancer as it would decimate many, many, many jobs and the GDP of the USA and some other countries world wide. Sounds like I am a "conspiracy" yokel but it has been sitting on the shelf for years needing only a few million dollars at most to be brought to the forefront of cancer research and not ONE agency has shown any interest in moving forward this monumental finding in medical research and development. If we found a way to make energy totally clean, no cost, and able to be transmitted with no losses would that technology be left to rot for years? This is about how revolutionary Kevetrin could be for cancer research and containment and the lives saved would be huge.
Bottom line: IPIX is the investment of a lifetime, bar none, for anybody looking for an investment that could bring them wealth. We are at the cusp this very weekend of starting the long climb in share price as CV19 will be the first indication to bring in funds and that will rocket launch the blossoming of Brilacidin as perhaps the most widely used drug in medical history (though it will be years for B to be completely developed, just as a high grade mine takes years to fully come to fruition. Kevetrin should also finally get the pill developed later this year as funds become available to finish the tox tests and become another star in clinical trials paid for by all BPs looking to improve their cancer treatments. FYI, Kevetrin P1 clinical trial had to be stopped because Dana-Farber could not get any patients to have negative side effects that would have shown they had reached a negative end point of the trial. It has also been tested for efficacy and shown extremely strong results but these were small tests and showed that the body cleared K so quickly that it had to be put into a pill form so patients could take every so many hours rather than being continually hooked up to an IV. That is why the pill form is so urgently needed to advance progress of K.
